A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients with Advanced Malignancies
The purpose of this study is the test the safety of a study drug called DCC-2618 in participants with KIT or PDGFRA mutant GIST who have failed prior treatments, and participants with Systemic Mastocytosis or other hematologic malignancies. The study drug has been tested in animals, but not people.
KIT or PDGFRA mutant GIST
Systemic Mastocytosis or other hematologic malignancies
Age >18 with confirmed GIST that has failed prior treatments or have Systemic Mastocytosis or other hematologic malignancies. Tests, procedures and a complete review of medical history will be done to confirm eligibility.
18 - 120
Healthy Volunteers Needed
Duration of Participation
For up to two years if there is continued benefit or until a commercial supply is available. A 30 day safety period is also included once the study drug period ends.
Knight Clinical Trials Information Line
Deciphera Pharmaceuticals, LLC